{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:44Z","timestamp":1793805944780,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:30:29Z","timestamp":1782984629000},"page":"272-281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size\u2013dependent survival in pT3N0M0 clear cell renal cell carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-6115","authenticated-orcid":false,"given":"Ethan","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Magi-Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-9615","authenticated-orcid":false,"suffix":"III","given":"James E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.005_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0003","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0004","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/ijc.34793","article-title":"Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non-metastatic renal cell carcinoma: systematic review and meta-analysis","volume":"154","author":"Majdoub","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0006","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0007","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0009","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","article-title":"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"402","author":"Ryan","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0010","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0011","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0012","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114146","article-title":"Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma","volume":"207","author":"Luke","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0014","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2019.11.036","article-title":"Risk factors for upstaging, recurrence, and mortality in clinical T1-2 renal cell carcinoma patients upstaged to pT3a disease: an international analysis utilizing the 8th edition of the tumor-node-metastasis staging criteria","volume":"138","author":"Hamilton","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5152\/tud.2023.22072","article-title":"Oncologic outcomes and predictors in patients with stage PT3aNxM0 renal cell carcinoma following radical nephrectomy","volume":"49","author":"Soltani","year":"2023","journal-title":"Urol Res Pract"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jjco\/hyy200","article-title":"Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma","volume":"49","author":"Sugiyama","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.09.010","article-title":"Reclassification of pathologically upstaged T3a renal cell Carcinoma is associated with enhanced alignment of outcomes: analysis of the National Cancer Database","volume":"43","author":"Puri","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0019","series-title":"R: a language and environment for statistical computing","year":"2024"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0020","series-title":"A package for survival analysis in R","author":"Therneau","year":"2024"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4602","article-title":"LITESPARK-022: a phase 3 study of pembrolizumab + belzutifan as adjuvant treatment of clear cell renal cell carcinoma (ccRCC)","volume":"40","author":"Choueiri","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0023","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.juro.2009.01.027","article-title":"Tumor size is associated with malignant potential in renal cell carcinoma cases","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0024","doi-asserted-by":"crossref","first-page":"E481","DOI":"10.1111\/j.1464-410X.2012.11173.x","article-title":"The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases","volume":"110","author":"Zhang","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0026","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2018.06.003","article-title":"The probability of aggressive versus indolent histology based on renal tumor size: implications for surveillance and treatment","volume":"74","author":"Bhindi","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14113908","article-title":"Positive surgical margins in clear cell renal cell carcinoma: prognostic impact and implications for risk stratification and adjuvant therapy","volume":"14","author":"Garofano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0028","doi-asserted-by":"crossref","first-page":"121.e15","DOI":"10.1016\/j.urolonc.2025.10.014","article-title":"Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma","volume":"44","author":"Garofano","year":"2026","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0029","doi-asserted-by":"crossref","first-page":"S1309","DOI":"10.1016\/j.annonc.2025.08.3225","article-title":"2609P Clinical performance of a tumor-informed whole genome-based (WGS) ctDNA assay for recurrence detection and treatment response monitoring in localized and advanced\/metastatic renal cell carcinoma (RCC)","volume":"36","author":"Suri","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaoncol.2022.6296","article-title":"Adoption of innovative therapies across oncology practices-evidence from immunotherapy","volume":"9","author":"Carroll","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0031","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oncolo\/oyac266","article-title":"Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy","volume":"28","author":"Atkinson","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0032","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","article-title":"The National Cancer Database conforms to the standardized framework for registry and data quality","volume":"31","author":"Palis","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35525","article-title":"Comparison of incident breast cancer cases in the largest national US tumor registries","volume":"131","author":"Plichta","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0034","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.urolonc.2025.08.004","article-title":"Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone","volume":"44","author":"Barbakoff","year":"2026","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2020.02.003","article-title":"Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era","volume":"38","author":"Takagi","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0036","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0037","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/JU.0000000000004705","article-title":"Risk factors for first-year recurrence in patients with synchronous metastatic renal cell carcinoma undergoing cytoreductive nephrectomy and complete metastasectomy","volume":"214","author":"Ghasemzadeh","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.12347","article-title":"Survival outcomes associated with cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma","volume":"5","author":"Chakiryan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.06.005_bib0039","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7289","article-title":"YIA25-001: molecular residual disease (MRD) guided adjuvant therapy in renal cell carcinoma (RCC) - the MRD GATE RCC study","volume":"23","author":"Basu","year":"2025","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:06Z","timestamp":1793802486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005600"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.005","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size\u2013dependent survival in pT3N0M0 clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}